(News Bulletin 247) – The title Pharnext (+15%) jumped on the stock market on Tuesday following the publication of a study valuing the biopharmaceutical company at levels much higher than those of its current market capitalization.
In a research note published yesterday evening, analysts at Edison Investment Research indicate that their valuation of Pharnext is now at 217 million euros (vs. 269 million euros previously), or 0.25 euros per share. basic.
By way of comparison, Pharnext’s market valuation is currently around 700,000 euros.
In its study, the economic intelligence office explains that it continues to attribute a 70% probability of success to PXT3003, the drug candidate developed by the company for the treatment of Charcot-Marie-Tooth disease of the 1A.
However, the research firm says it now applies a haircut of 15%, rather than 12.5%, as part of its methodology due to the recent bout of volatility within the biotechnology segment and the increase in risks. macroeconomics.
Note that Pharnext is a client of Edison Investment Research, which means that its teams provide investment services to the company.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
_210056.jpg?fit=%2C&ssl=1)
